Live Quote · NASDAQMBXHealthcare· Biotechnology

MBX Biosciences, Inc. Common Stock

$57.80 3.36%(+$1.88)
TickerSpark Score
53/100
Mixed
47
Valuation
20
Profitability
15
Growth
84
Health
100
Momentum

Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MBX research report →

52-Week Range99% of range
Low
$9.63
Current
$57.80
High
$58.50
Company Overviewmbxbio.com

About the company

MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials.

CEO
Peter Kent Hawryluk
IPO
2000
Employees
43
HQ
Carmel, IN, US

Price Chart

+368.78% · this period
$57.80$33.77$9.74Jul 02Dec 31Jul 02
Valuation
Market Cap
$1.94B
P/E
-26.27
P/S
0.00
P/B
6.15
EV/EBITDA
-21.96
Div Yield
0.00%
Profitability
Gross Margin
0.00%
Op Margin
0.00%
Net Margin
0.00%
ROE
-24.50%
ROIC
-22.54%
Growth & Income
Revenue
$0 · 0.00%
Net Income
$-86,971,000 · -40.45%
EPS
$-2.38 · -28.65%
Op Income
$-98,055,000
FCF YoY
-47.38%
Performance & Tape
52W High
$58.50
52W Low
$9.63
50D MA
$36.48
200D MA
$30.38
Beta
0.16
Avg Volume
762.96K

Get TickerSpark's AI analysis on MBX

Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.

Get Pro Access →

Already have an account? Log in

Form 4 · Filings

Recent insider transactions

Who's buying, who's selling, and how much.

DateInsiderTypeShares
Jun 4, 26Mathers Edward Tother12,500
Jun 4, 26Pescovitz Ora H.other12,500
Jun 4, 26Heron Patrick Jother12,500
Jun 4, 26Stelzer Laurieother12,500
Jun 4, 26Hoerter Steven L.other12,500
Jun 4, 26Ryder Stevenother12,500
Jun 4, 26Aynechi Tibaother12,500
May 8, 26Azoulay Salomonother55,000
May 8, 26Azoulay Salomonother55,000
May 8, 26Azoulay Salomonother15,003
Coverage · MBX

Our MBX coverage

Recent articles, reports, and earnings notes.

On-Demand Research

No research on MBX yet

For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.

Generate MBX report →
Internal Compare

Similar companies

Peers in the same neighborhood.